Supplementation with folic acid should be given because there is hemolytic anemia. HbH patients are at risk of clinical manifestations with oxidative damage. Blood counts should be monitored, and transfusional intervention may be required during periods of oxidant stress, such as infection or oxidant drug use. Patients must be monitored carefully for complications of chronic transfusion and given iron chelation support as needed, especially during the second and third decades of life. Patients require careful genetic counseling.